OBJECTIVES

1. Communicate appreciation, support, and ongoing investment in our clinical research faculty and staff
2. Feature the capabilities of UChicago Medicine as a partner in clinical trials
3. Celebrate contributions of BSD faculty and staff on medical and healthcare innovation

AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Title / Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. – 9:30 a.m.</td>
<td>Clinical Trial Celebration hosted by the Office of Clinical Research</td>
<td>Zoom</td>
</tr>
<tr>
<td></td>
<td>This 30 minute Zoom meeting will bring together clinical research staff and professionals to recognize their contributions and achievements. Individuals nominated for clinical trial day awards will be announced.</td>
<td></td>
</tr>
<tr>
<td>12:00 – 1:00 p.m.</td>
<td>Medical Innovation through Academic-Industry Partnerships in Clinical Trials</td>
<td>Zoom</td>
</tr>
<tr>
<td></td>
<td>This panel will feature leading physician-researchers and life science executives who are driving medical innovation forward through clinical trial partnerships. The discussion will explore three ways in which Academic-Industry clinical trial partnerships can take shape: Investigator initiated clinical trials; industry sponsored clinical trials; and licensing assets developed within universities to take through the clinical trial phases to market.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator</strong>: Walter Stadler, Fred C. Buffett Professor of Medicine, Dean for Clinical Research</td>
<td></td>
</tr>
</tbody>
</table>
|                  | **Panelists**:  
|                  | • Krishna Balakrishnan, Deputy Director, Office of Strategic Alliances, National Center for Advancing Translational Sciences  
|                  | • Ellen Bolotin, Executive Medical Director, Global Development Leader, AbbVie  
|                  | • Hedy Kindler, Professor of Medicine  
|                  | • Olatoyosi Odenike, Professor of Medicine  
|                  | • David Rubin, Joseph B Kirsner Professor of Medicine  
|                  | • Sonali Smith, Elwood V. Jensen Professor of Medicine  
|                  | • Julian Solway, Walter L. Palmer Distinguished Service Professor of Medicine, Dean for Translational Research |          |
Medical Innovation through Academic-Industry Partnerships in Clinical Trials

Panelist Questions:

- Please introduce yourself being sure to highlight your clinical specialty, your research areas of interest, and your leadership role (1 min per panelist)

- Dr. Smith
  - The majority of clinical trials at the UCMC are in cancer. What are some of the keys to this success?
  - Size and success can sometimes create operational challenges. What are the biggest challenges and opportunities for enhancing operational efficiency?

- Dr. Odenike
  - What are some of the unique challenges of recruiting patients with hematologic malignancies to clinical trials?
  - How can partnerships help with recruitment and medical innovation in cancer?

- Dr. Rubin
  - What are the biggest unmet needs for treatment of hepatic and gastroenterologic diseases and how are the GI faculty contributing?
  - How do you work with industry collaborators to further your GI research mission?

- Dr. Kindler
  - What are some of major clinical research interests in the DOM outside of gastroenterology and cancer?
  - Where do you see opportunities to enhance and grow our collaborations between academic researchers and industry partners?

- Dr. Bolotin
  - What are the keys to successful industry-academic partnerships from your perspective?
  - How should Chicago area academic and the pharmaceutical/device industry work together to enhance the region’s healthcare and economic impact?

- Dr. Balakrishnan
  - What role does NCATS play in the drug development process?
  - How does the work of NCATS fit into the medical product development process? Do you have any success stories to point to?

- Dr. Solway
  - What are the unique aspects of the Chicago ITM in terms of supporting development of clinical trials?
  - How can early translational funding impact the ability to get partnerships and funding for later phase clinical trials?